Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Organisation › Details

TxCell S.A. (Euronext Paris: TXCL)

TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell’s lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, the TxCell's second drug candidate developed as a treatment for autoimmune uveitis, is expected to enter in clinical studies in the near future. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 47 employees. *

 

Period Start 2001-01-01 splitoff
  Predecessor Inserm (National Institute for Health and Medical Research, FR)
Products Industry ASTrIA technology (Antigen Specific Treg for Inflammation and Autoimmunity)
  Industry 2 ENTrIA technology (Engineered Treg for Inflammation and Autoimmunity)
Persons Person Boissel, Stéphane (SparingVision 202010– CEO before Sangamo + TxCell + Genclis + Transgene + Innate Pharma + Lazard)
  Person 2 Flipo, Raphaël (TxCell 201509 CFO)
     
Region Region Valbonne
  Country France
  Street Allée de la Nertière
Les Cardoulines HT1
  City 06560 Valbonne – Sophia Antipolis
  Tel +33-4-9721-8300
    Address record changed: 2024-01-05
     
Basic data Employees B: 11 to 50 (2017-12-31)
  Currency EUR
  Annual sales 2,234,000 (revenue + other income (2017) 2017-12-31)
  Profit -10,911,000 (2016-12-31)
  Cash 4,910,000 (2017-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2024-02-12

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for TxCell S.A. (Euronext Paris: TXCL)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top